Recombinant Human Melanin-concentrating hormone receptor 2 (MCHR2)

What is MCHR2 and how does it functionally differ from MCHR1?

Melanin-concentrating hormone receptor 2 (MCHR2), also known as G-protein coupled receptor 145 (GPR145), is a seven-transmembrane G protein-coupled receptor encoded by the MCHR2 gene in humans . While both MCHR1 and MCHR2 bind melanin-concentrating hormone (MCH) and share some functional overlap, they exhibit distinct differences in their expression patterns, signaling pathways, and evolutionary conservation. Both receptors primarily function to regulate skin color, but additionally play roles in regulating food intake, energy expenditure, behavior, and emotional responses .

The key methodological consideration when studying MCHR2 versus MCHR1 is their differential expression across species. Unlike MCHR1, which is widely conserved, MCHR2 is only found in humans, dogs, ferrets, and some other primates and carnivores, but notably absent in common laboratory rodents including mice and rats . This species-specific expression pattern has significantly delayed research into MCHR2 as a therapeutic target, as early pharmaceutical research typically relies on rodent models.

What cellular models are available for studying human MCHR2?

Several recombinant cell systems have been developed to enable the study of human MCHR2 in controlled laboratory settings:

• CHO dhfr- cells expressing full-length human MCHR2/GPR145 (GenBank Accession Number NM_032503.1)

• U2OS cells (human osteosarcoma cell line) for MCHR-related redistribution assays

For functional characterization of MCHR2, stable cell lines expressing the receptor can be maintained in Alpha-MEM supplemented with 10% FBS and 400 μg/mL G418 . These cells remain stable in culture for a minimum of two months, making them suitable for extended experimental protocols.

When designing experiments with these cellular models, researchers should consider:

• Calcium flux assays can be used to measure dose-dependent stimulation upon treatment with MCH or other ligands

• Internalization of MCHR2-EGFP fusion proteins can be monitored to assess receptor trafficking and activation

• High-content imaging approaches allow for visualization of receptor redistribution following agonist treatment

What gene expression changes occur following MCHR2 activation?

Treatment of human cells expressing MCHR2 with MCH results in specific gene expression changes that provide insight into the receptor's downstream signaling pathways. Notably, MCHR2 activation leads to:

• Upregulation of IDH3A, PCK1, and PFKFB4

• Downregulation of INSIG2 and ACOT8

These gene expression changes suggest involvement in metabolic pathways, consistent with the receptor's role in energy homeostasis. When designing experiments to measure such changes, researchers should consider time-dependent effects, dose-response relationships, and cell-type specific variations in expression patterns.

Transcriptome analysis represents a powerful approach for comprehensively identifying gene expression changes following MCHR2 activation. For instance, when studying potential therapeutic compounds targeting MCHR2, researchers have employed transcriptome analysis on multiple cell lines (A375, A549, MCF7, and PC3) following compound administration (typically 10 μM for 6 hours) . This approach has proven valuable for identifying novel indications for MCHR2-targeting molecules.

How can researchers overcome limitations in studying MCHR2 due to its absence in common rodent models?

The absence of MCHR2 in mice and rats presents a significant challenge for researchers, as these species are the predominant models for early pharmaceutical research . Several methodological approaches can help overcome this limitation:

• Humanized mouse models: Generating transgenic mice expressing human MCHR2 under tissue-specific promoters

• Alternative animal models: Utilizing species that naturally express MCHR2, such as dogs or ferrets, though these come with ethical and practical constraints

• In vitro cellular models: Employing recombinant cell systems expressing human MCHR2, such as the CHO dhfr- cells with full-length human MCHR2/GPR145 (NM_032503.1)

• Ex vivo tissue culture: Working with human tissue samples that express MCHR2 naturally

• Computational approaches: Leveraging machine learning-based prediction models to identify MCHR2 antagonists, as demonstrated in the identification of compounds like KRX-104130

The optimal experimental design typically involves a combination of these approaches. Initial screening may be performed using in vitro cellular models and computational approaches, followed by validation in more complex systems such as organoids or alternative animal models that express MCHR2.

What challenges exist in developing MCHR2 antagonists and how can they be addressed?

Developing specific antagonists for MCHR2 presents several challenges, particularly regarding cardiotoxicity. A significant issue in developing MCHR receptor antagonists is that their binding sites share structural similarities with the human Ether-à-go-go-Related Gene (hERG) channel . Inhibition of hERG can cause cardiotoxicity, which has led to the failure of multiple MCHR antagonist candidates during clinical development.

A methodological approach to overcome this challenge involves:

• Virtual screening using machine learning models: Implementing dual prediction models that simultaneously assess MCHR2 binding affinity and potential hERG-induced cardiotoxicity

• Structure-activity relationship (SAR) studies: Developing compounds with structural modifications that retain MCHR2 affinity while reducing hERG binding

• Transcriptome-based drug repositioning: Exploring additional therapeutic indications for successful MCHR2 antagonists to improve their risk-benefit profile

One successful example of this approach is the identification of KRX-104130, which demonstrates potent MCHR2 antagonistic activity without cardiotoxicity . This compound was discovered through virtual screening using MCHR2 binding affinity prediction models coupled with hERG-induced cardiotoxicity prediction models.

What methodological approaches are available for measuring MCHR2 activation and signaling?

Several experimental approaches can be employed to study MCHR2 activation and downstream signaling:

Calcium Flux Assays:

• Utilize Multiscreen Calcium 1.0 No Wash Assay Kit to measure dose-dependent stimulation of calcium flux upon ligand treatment

• Allow for quantitative measurement of receptor activation in real-time

Receptor Redistribution Assays:

• Monitor the internalization of membrane-localized MCHR2-EGFP fusion proteins using high-content imaging

• Provide visual confirmation of receptor activation and trafficking

Transcriptome Analysis:

• Measure changes in gene expression following MCHR2 activation using RNA-seq or microarray approaches

• Identify downstream pathways and potential new therapeutic indications

Protein Expression Analysis:

• Quantify changes in protein levels (such as LDLR) in response to MCHR2 modulation using Western blotting or ELISA

• Confirm that transcriptional changes translate to functional protein alterations

When designing experiments utilizing these methods, researchers should consider:

• Appropriate positive and negative controls

• Time-dependent responses (acute vs. chronic activation)

• Dose-response relationships

• Cell type-specific effects

• Potential cross-talk with other signaling pathways

How can transcriptome analysis be utilized to identify novel functions of MCHR2?

Transcriptome analysis represents a powerful approach for uncovering new functions and therapeutic applications of MCHR2. This methodology has successfully identified unexpected roles for MCHR2-targeting compounds:

• Experimental Design: Treat appropriate cell lines (such as A375, A549, MCF7, and PC3) with the compound of interest (typically 10 μM) for 6 hours in both control and treatment groups

• Data Collection: Perform RNA sequencing in triplicate to account for experimental variability, using the average value for comparison

• Data Analysis: Calculate fold change (FC) by dividing the gene expression value of the control group by that of the treatment group, expressing positive or negative values based on direction of change

• Validation Studies: Confirm key findings with orthogonal methods such as qPCR or protein expression analysis

For example, transcriptome analysis of KRX-104130-treated HepG2 cells revealed upregulation of the LDLR gene in a concentration-dependent manner, which was subsequently validated at both mRNA and protein levels . This finding suggests potential applications for MCHR2 antagonists in cholesterol management, expanding their therapeutic potential beyond traditional applications related to energy homeostasis.

What control measures should be implemented in MCHR2 functional assays?

When designing experiments to study MCHR2 function, several control measures should be implemented to ensure robust and reproducible results:

• Positive Controls: Include known MCHR2 agonists such as synthetic MCH peptide at established effective concentrations (typically 5 μM)

• Negative Controls: Utilize vehicle controls (typically DMSO at equivalent concentrations) to account for non-specific effects

• Concentration Series: Employ dose-response curves rather than single concentrations to establish EC50/IC50 values for compounds of interest

• Time Course Studies: Assess both immediate and delayed responses to capture the full spectrum of MCHR2 signaling events

• Cell Viability Assessments: Monitor potential cytotoxicity using secondary high-content outputs such as:

  • Nucleus size, shape, and intensity (indicators of DNA damage, cell cycle effects, and apoptosis)

  • Cell number, size, and shape (markers of acute cytotoxicity and apoptosis)

  • Cell fluorescence intensity (parameter for compound cytotoxicity and fluorescence)

• Specificity Controls: Compare effects on MCHR2-expressing cells with parental cells lacking the receptor to confirm receptor-specific actions

These control measures help distinguish true MCHR2-mediated effects from experimental artifacts, enhancing the reliability and reproducibility of research findings.